Exact Mass: 678.3743944

Exact Mass Matches: 678.3743944

Found 63 metabolites which its exact mass value is equals to given mass value 678.3743944, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Gingerglycolipid B

2-Hydroxy-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9Z,12Z)-octadeca-9,12-dienoic acid

C33H58O14 (678.3826368)


Gingerglycolipid B is found in ginger. Gingerglycolipid B is from Zingiber officinale (ginger). From Zingiber officinale (ginger). Gingerglycolipid B is found in herbs and spices and ginger.

   

PA(10:0/6 keto-PGF1alpha)

[(2R)-3-(decanoyloxy)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)propoxy]phosphonic acid

C33H59O12P (678.3743944)


PA(10:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/6 keto-PGF1alpha), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(6 keto-PGF1alpha/10:0)

[(2R)-2-(decanoyloxy)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)propoxy]phosphonic acid

C33H59O12P (678.3743944)


PA(6 keto-PGF1alpha/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/10:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/TXB2)

[(2R)-3-(decanoyloxy)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H59O12P (678.3743944)


PA(10:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/TXB2), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(TXB2/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H59O12P (678.3743944)


PA(TXB2/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/10:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   
   

24-O-(3-O-Methyl-4-O-Sulfo-beta-D-xylofuranoside)-Cholestane-3,6,8,15,24-pentol

24-O-(3-O-Methyl-4-O-Sulfo-beta-D-xylofuranoside)-Cholestane-3,6,8,15,24-pentol

C33H58O12S (678.3648788)


   

21-O-beta-D-glucopyranosyl-18R-hydroxydihydroalloprotolichesterinate 21-O-alpha-L-rhamnopyranoside

21-O-beta-D-glucopyranosyl-18R-hydroxydihydroalloprotolichesterinate 21-O-alpha-L-rhamnopyranoside

C33H58O14 (678.3826368)


   

2,3,4-tri(5-methylhexanoyl)-alpha-D-glucopyranosyl-beta-D-fructofuranoside|2,3,4-Tri(5-methylhexanoyl)-??-D-glucopyranosyl-??-D-fructofuranoside

2,3,4-tri(5-methylhexanoyl)-alpha-D-glucopyranosyl-beta-D-fructofuranoside|2,3,4-Tri(5-methylhexanoyl)-??-D-glucopyranosyl-??-D-fructofuranoside

C33H58O14 (678.3826368)


   

18-O-alpha-L-rhamnopyranosyl-18S-hydroxyneodihydroprotolichesterinate 21-O-beta-D-glucopyranoside

18-O-alpha-L-rhamnopyranosyl-18S-hydroxyneodihydroprotolichesterinate 21-O-beta-D-glucopyranoside

C33H58O14 (678.3826368)


   
   

3-dodecanoyl-3-isobutanoyl-4-(3-methylbutanoyl)sucrose

3-dodecanoyl-3-isobutanoyl-4-(3-methylbutanoyl)sucrose

C33H58O14 (678.3826368)


   
   

LRDLY

Leu Arg Asp Leu Tyr

C31H50N8O9 (678.3700570000001)


   

Gingerglycolipid B

2-hydroxy-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9Z,12Z)-octadeca-9,12-dienoate

C33H58O14 (678.3826368)


   

DGMG 18:2

1-(9Z,12Z-octadecadienoy)l-3-O-(6-O-alpha-D-galactosyl-beta-D-galactosyl)-sn-glycerol

C33H58O14 (678.3826368)


   

3-Lauryl-3-isobutanoyl-4-(isovaleryl)sucrose

3-Lauryl-3-isobutanoyl-4-(isovaleryl)sucrose

C33H58O14 (678.3826368)


   

PA(10:0/6 keto-PGF1alpha)

PA(10:0/6 keto-PGF1alpha)

C33H59O12P (678.3743944)


   

PA(6 keto-PGF1alpha/10:0)

PA(6 keto-PGF1alpha/10:0)

C33H59O12P (678.3743944)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

PI P-20:1/4:1 or PI O-20:2/4:1

PI P-20:1/4:1 or PI O-20:2/4:1

C33H59O12P (678.3743944)


   
   

PI P-24:2 or PI O-24:3

PI P-24:2 or PI O-24:3

C33H59O12P (678.3743944)


   

2-hydroxy-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl octadeca-9,12-dienoate

2-hydroxy-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl octadeca-9,12-dienoate

C33H58O14 (678.3826368)


   

2,3,4-tri(5-methylhexanoyl)-α-d-glucopyranos-yl-β-d-fructofuranoside

NA

C33H58O14 (678.3826368)


{"Ingredient_id": "HBIN003890","Ingredient_name": "2,3,4-tri(5-methylhexanoyl)-\u03b1-d-glucopyranos-yl-\u03b2-d-fructofuranoside","Alias": "NA","Ingredient_formula": "C33H58O14","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21948","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(2r,3r,4s,5r,6r)-6-{[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-2-(hydroxymethyl)-4,5-bis[(5-methylhexanoyl)oxy]oxan-3-yl 5-methylhexanoate

(2r,3r,4s,5r,6r)-6-{[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-2-(hydroxymethyl)-4,5-bis[(5-methylhexanoyl)oxy]oxan-3-yl 5-methylhexanoate

C33H58O14 (678.3826368)


   

(2r)-2-hydroxy-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9z,12z)-octadeca-9,12-dienoate

(2r)-2-hydroxy-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9z,12z)-octadeca-9,12-dienoate

C33H58O14 (678.3826368)


   

(6s,6ar,10as,14r)-12-hexanoyl-10a,13-dihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-6a,14-dihydro-6h-5,11-dioxapentaphene-1,3,7,9-tetrone

(6s,6ar,10as,14r)-12-hexanoyl-10a,13-dihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-6a,14-dihydro-6h-5,11-dioxapentaphene-1,3,7,9-tetrone

C40H54O9 (678.3767634000001)


   

[(1r,3s,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,7-trihydroxy-1-[(2r,5s)-5-{[(2r,3r,4r,5s)-3-hydroxy-5-(hydroxymethyl)-4-methoxyoxolan-2-yl]oxy}-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-yl]oxidanesulfonic acid

[(1r,3s,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,7-trihydroxy-1-[(2r,5s)-5-{[(2r,3r,4r,5s)-3-hydroxy-5-(hydroxymethyl)-4-methoxyoxolan-2-yl]oxy}-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-yl]oxidanesulfonic acid

C33H58O12S (678.3648788)


   

(2s)-2-hydroxy-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9z,12z)-octadeca-9,12-dienoate

(2s)-2-hydroxy-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9z,12z)-octadeca-9,12-dienoate

C33H58O14 (678.3826368)


   

2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)-4,5-bis[(5-methylhexanoyl)oxy]oxan-3-yl 5-methylhexanoate

2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)-4,5-bis[(5-methylhexanoyl)oxy]oxan-3-yl 5-methylhexanoate

C33H58O14 (678.3826368)


   

[(3s,4s,5s,6s)-6-{[(4r,7r)-7-[(1r,3s,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]octan-4-yl]oxy}-5-hydroxy-4-methoxyoxan-3-yl]oxidanesulfonic acid

[(3s,4s,5s,6s)-6-{[(4r,7r)-7-[(1r,3s,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]octan-4-yl]oxy}-5-hydroxy-4-methoxyoxan-3-yl]oxidanesulfonic acid

C33H58O12S (678.3648788)


   

(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl (2s,3s,4r)-4-methyl-5-oxo-2-[(14r)-14-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentadecyl]oxolane-3-carboxylate

(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl (2s,3s,4r)-4-methyl-5-oxo-2-[(14r)-14-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentadecyl]oxolane-3-carboxylate

C33H58O14 (678.3826368)


   

[(1r,3as,3br,5r,5as,7r,9ar,9bs,11r,11as)-5-hydroxy-1-[(2r)-1-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-11-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-tetradecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxidanesulfonic acid

[(1r,3as,3br,5r,5as,7r,9ar,9bs,11r,11as)-5-hydroxy-1-[(2r)-1-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-11-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-tetradecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxidanesulfonic acid

C33H58O12S (678.3648788)


   

12-hexanoyl-10a,13-dihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-6a,14-dihydro-6h-5,11-dioxapentaphene-1,3,7,9-tetrone

12-hexanoyl-10a,13-dihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-6a,14-dihydro-6h-5,11-dioxapentaphene-1,3,7,9-tetrone

C40H54O9 (678.3767634000001)


   

2-hydroxy-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9z,12z)-octadeca-9,12-dienoate

2-hydroxy-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl (9z,12z)-octadeca-9,12-dienoate

C33H58O14 (678.3826368)


   

[(3r,4r,5r,6s)-6-{[(3s,6r)-6-[(1r,3s,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-2-methylheptan-3-yl]oxy}-5-hydroxy-4-methoxyoxan-3-yl]oxidanesulfonic acid

[(3r,4r,5r,6s)-6-{[(3s,6r)-6-[(1r,3s,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-2-methylheptan-3-yl]oxy}-5-hydroxy-4-methoxyoxan-3-yl]oxidanesulfonic acid

C33H58O12S (678.3648788)